Piper Sandler Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $24

Piper Sandler analyst Edward Tenthoff has initiated coverage on Generate Biomedicines (NASDAQ: GENB) with an Overweight rating. The firm has set a price target of $24 for the company's stock.